Home > Publications . Search All . Browse All . Country . Browse PSC Pubs . PSC Report Series

PSC In The News

RSS Feed icon

Davis-Kean et al. link children's self-perceptions to their math and reading achievement

Yang and Mahajan examine how hurricanes impact migration to the US

Patrick and colleagues analyze high-intensity drinking among adolescents

More News

Highlights

Pamela Smock elected to PAA Committee on Publications

Viewing the eclipse from ISR-Thompson

Paula Fomby to succeed Jennifer Barber as Associate Director of PSC

PSC community celebrates Violet Elder's retirement from PSC

More Highlights

Next Brown Bag

Mon, Sept 11, 2017, noon:
Welcoming of Postdoctoral Fellows: Angela Bruns, Karra Greenberg, Sarah Seelye and Emily Treleaven

Evaluation of the FDA Warning Against Prescribing Citalopram at Doses Exceeding 40 mg

Archived Abstract of Former PSC Researcher

Zivin, Kara, Paul N. Pfeiffer, Amy S.B. Bohnert, Dara Ganoczy, Frederic C. Blow, Brahmajee K. Nallamothu, and Helen C. Kales. 2013. "Evaluation of the FDA Warning Against Prescribing Citalopram at Doses Exceeding 40 mg." American Journal of Psychiatry, 170(6): 642-650.

Objective: A recent Food and Drug Administration (FDA) warning cautioned that citalopram dosages exceeding 40 mg/day may cause abnormal heart rhythms, including torsade de pointes. The authors assessed relationships between citalopram use and ventricular arrhythmias and mortality.

Method: A cohort study was conducted using Veterans Health Administration data between 2004 and 2009 from depressed patients who received a prescription for citalopram (N=618,450) or for sertraline (N=365,898), a comparison medication with no FDA warning. Cox regression models, adjusted for demographic and clinical characteristics, were used to examine associations of antidepressant dosing with ventricular arrhythmia and cardiac, non-cardiac, and all-cause mortality.

Results: Citalopram daily doses >40 mg were associated with lower risks of ventricular arrhythmia (adjusted hazard ratio=0.68, 95% CI=0.61-0.76), all-cause mortality (adjusted hazard ratio=0.94, 95% (I=0.90-0.99), and noncardiac mortality. (adjusted hazard ratio=0.90, 95% CI=0.86-0.96) compared with daily doses of 1-20 mg. No increased risks of cardiac mortality were found. Citalopram daily doses of 21-40 mg were associated with lower risks of ventricular arrhythmia (adjusted hazard ratio=0.80, 95% CI=0.74-0.86) compared with dosages of 1-20 mg/day but did not have significantly different risks of any cause of mortality. The sertraline cohort revealed similar findings, except there were no significant associations between daily dose and either all-cause or noncardiac mortality.

Conclusions: This large study found no elevated risks of ventricular arrhythmia or all-cause, cardiac, or noncardiac mortality associated with citalopram dosages >40 mg/day. Higher dosages were associated with fewer adverse outcomes, and similar findings were observed for a comparison medication, sertraline, not subject to the FDA warning. These results raise questions regarding the continued merit of the FDA warning.

DOI:10.1176/appi.ajp.2013.12030408 (Full Text)

Browse | Search : All Pubs | Next